IP Library Granted Patent US 11,795,455
Granted Patent B2
US 11,795,455 · App. 16/049,042 · Granted Oct 24, 2023

RNA cleavage-induced transcript stabilizer and uses thereof

Inventors: Ron Weiss (Newton, MA); Breanna E. DiAndreth (Cambridge, MA)
Assignee: Massachusetts Institute of Technology
C12N15/113A61K48/0066C12N15/63C12N15/67C12N2310/121C12N2310/122C12N2310/126C12N2310/14C12N2840/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,795,455
App. No.
16/049,042
Granted
Oct 24, 2023
Kind
B2
Abstract

Provided herein are genetic circuits and encoded RNA transcripts that produce an output molecule in response to an RNA cleavage event that removes a degradation signal. In some embodiments, the genetic circuits described herein may be used for detecting RNA cleaver activities (e.g., in a cell). Methods of using the genetic circuits described herein in diagnostic or therapeutic applications are also provided.

Claims (18)

1. A composition comprising:

(i) a first genetic circuit encoding an RNA transcript, the genetic circuit comprising

a first promoter operably linked to a nucleotide sequence encoding an output molecule followed, from 5′ to 3′, by an RNA stabilizer, a cleavage site for an RNA cleaver, and a degradation signal, wherein the RNA transcript comprises one or more recognition sites for an RNA repressor operably linked to the nucleotide sequence encoding the output molecule; and

(ii) a second genetic circuit comprising a second promoter operably linked to a nucleotide sequence encoding the RNA repressor, and one or more cleavage sites for the RNA cleaver.

2. The composition of claim 1 , further comprising:

(iii) a third genetic circuit comprising a third promoter operably linked to a nucleotide sequence encoding the RNA cleaver.

3. The composition of claim 1 , wherein the RNA cleaver is selected from the group consisting of: endoribonucleases, RNAi molecules, and ribozymes.

4. The composition of claim 1 , wherein the RNA repressor is an RNA binding protein.

5. The composition of claim 4 , wherein the RNA binding protein is fused to a modifying domain.

6. The composition of claim 1 , wherein the RNA stabilizer is selected from the group consisting of: MALAT1 triplex, MENβ triplex, KSHV PAN triplex, histone stem loop, and a polyA signal.

7. A cell comprising the first and second genetic circuits of claim 1 .

8. The cell of claim 7 , wherein the first and second genetic circuits are inserted into the genome of the cell.

9. A method comprising maintaining the cell of claim 7 .

10. The method of claim 2 , further comprising detecting the output molecule.

11. The method of claim 10 , further comprising classifying the cell.

12. A method comprising delivering the RNA transcript encoded by the first genetic circuit of claim 1 to a cell and detecting the output molecule.

13. A method of treating a disease or disorder comprising administering an effective amount of a composition comprising the composition of claim 2 to a subject in need thereof, wherein the output molecule is a therapeutic molecule that is effective for treating the disease or disorder.

14. An RNA transcript encoded by the first genetic circuit of claim 1 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 29, 2019
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048180/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: WEISS, RON; DIANDRETH, BREANNA E.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 047914/0146 →
Continuity (2)
Provisional Application 62539375 · Jul 31, 2017
Related Publication 20190032054A1 · Jan 31, 2019
Cited By (1)
US 12,480,119